Ms Heng is chief investigator for several clinical studies
SIBA study- looking at inequality within the medical retina digital clinics
Wet AMD Burden Study- looking at treatment burden and efficacy across different types of antivegf to patients, carers and service providers.
She was also involved as principal and subinvestigator of numerous pivotal clinical trials including the 2RT RETILASE study and OZLASE study(one of the first studies to evaluate use of ozurdex steroid implant in diabetic macular oedema in the UK) in the course of her career.
She has made in excess of 50 international presentations across the world.
Ms Heng’s PhD was on preventative therapy in Age Related Macular Degeneration- ‘The use of the nanosecond laser technology to retard the onset of age related macular degeneration’. Her PhD is often used as a teaching guide for the pathophysiology of lasers.
Ms. Heng was involved in numerous phase II/III clinical trials for medical retinal diseases (AMD and diabetic retinopathy), including the OZLASE, TENAYA, and RHINE studies. These studies investigated new treatments or protocols for diabetic macular oedema and AMD.
Accepted for Publication: British Journal for Publication
Real-world early outcomes of intravitreal faricimab 6mg and aflibercept 2mg injection in diabetic macular oedema
Ms. Heng leads the Retina Digital Clinic at Moorfields Eye Hospital, where more than a thousand patients are reviewed on a weekly basis. She is keen on improving clinical governance within the sphere of digital medicine and benchmarking standards and quality within digital clinics.
She is also the Chief Investigator of a health inequality study to determine the barriers to, and acceptability of, digital clinics.
May 2025- Journal of Clinical Medicine
Jan 2025- British Medical Journal Open
Journal of French Ophthalmology
Eye 38, 168-172 (2024)pages168–172 (2024volume 38, pages168–172 (2024 volume 38, pages168–172 (2024
Heng LZ, R. Hamilton
Medicine in Ophthalmology (Dec 2018, Journal of Medicine)
Heng LZ, R. Hamilton